CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed/Refractory Primary Mediastinal B-cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05934448
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:17.625665+00:00
Published At: 2026-03-05T00:00:00+00:00
Record Updated At: 2026-03-05
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Primary Mediastinal Large B Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma Refractory", "Primary Mediastinal Large B-Cell Lymphoma Recurrent", "Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-05"
protocolSection.identificationModule.nctId: "NCT05934448"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of Pembrolizumab in Combination With Chimeric Antigen Receptor Therapy in Patients With Relapsed/Refractory Primary Mediastinal B-cell Lymphoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.